These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3513778

  • 1. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y, Hori H, Oka M, Nakamura H, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y, Taira N, Fujitani B, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
    [Abstract] [Full Text] [Related]

  • 4. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
    Takeyama K, Minato H, Nakatsuji K, Suzuki H, Nose I, Oka M, Hosoki K, Hatano N, Kadokawa T.
    Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
    [Abstract] [Full Text] [Related]

  • 5. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
    Takeyama K, Minato H, Ikeno A, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
    [Abstract] [Full Text] [Related]

  • 6. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
    Nambu K, Matsumoto K, Takeyama K, Hosoki K, Miyazaki H, Hashimoto M.
    Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
    [Abstract] [Full Text] [Related]

  • 7. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
    [Abstract] [Full Text] [Related]

  • 8. Antihypertensive mechanism of alacepril. Effects of its metabolites on the peripheral sympathetic nervous system.
    Minato H, Hosoki K, Hayashi K, Sawayama T, Kadokawa T, Hashimoto M.
    Arzneimittelforschung; 1989 Mar; 39(3):319-24. PubMed ID: 2547387
    [Abstract] [Full Text] [Related]

  • 9. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
    Matsumoto K, Miyazaki H, Fujii T, Yoshida K, Amejima H, Hashimoto M.
    Arzneimittelforschung; 1986 Mar; 36(1):40-6. PubMed ID: 3513776
    [Abstract] [Full Text] [Related]

  • 10. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G, Morimoto S, Shiomi M.
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [Abstract] [Full Text] [Related]

  • 11. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S.
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [Abstract] [Full Text] [Related]

  • 12. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
    Hosoki K, Takeyama K, Minato H, Fukuya F, Kawahara S, Kadokawa T.
    Arzneimittelforschung; 1986 Aug; 36(1):77-83. PubMed ID: 3006712
    [Abstract] [Full Text] [Related]

  • 13. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985 Aug; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
    Yamamoto S, Takemori E, Hasegawa Y, Nakao K, Inukai T, Nomura M, Morino K, Tsuchiyama M, Hasegawa K, Ikeda H.
    Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
    [Abstract] [Full Text] [Related]

  • 15. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
    Kurumiya S, Miura Y, Nakatsuji K, Dodo M, Hori M, Ito T.
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
    [Abstract] [Full Text] [Related]

  • 16. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 17. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
    Matsumoto K, Nambu K, Fujii T, Takeyama K, Miyazaki H, Hashimoto M.
    Arzneimittelforschung; 1986 Oct; 36(1):52-4. PubMed ID: 3006711
    [Abstract] [Full Text] [Related]

  • 18. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T.
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
    Mizuno K, Hashimoto S, Kunii N, Tani M, Niimura S, Yabe R, Watari H, Fukuchi S.
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.